Shire plc has filed its first submission to the U.S. FDA for the company’s new plasma manufacturing facility in Covington, GA. The facility will expand capacity by approximately 30% once fully operational. Commercial production is expected to begin in 2018. The submission is for the transfer of GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% Solution, a replacement therapy for primary humoral immunodeficiency (PI). The company expects to make a second submission to the FDA in 20...